BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FASgen, Inc. Announces Research and License Agreement With Centocor, Inc. (JNJ)


1/6/2009 6:44:57 AM

BALTIMORE, Jan. 6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research and Development division affiliates the opportunity to discover and develop novel small molecule inhibitors of the fatty acid biosynthesis pathway via selective inhibition of Fatty Acid Synthase (FAS) for use in Oncology. The FASgen researchers have extensive experience studying the over-expression of FAS, an enzyme over-expressed in virtually all solid tumors. The inhibition of FAS causes tumor cell apoptosis and holds promise for new therapeutic treatments for cancer.

The economic terms of the research collaboration were not disclosed.

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University. The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer. Additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders including diabetes, dysplipidemia fatty liver disease and non-alcoholic steatohepatitis. A final group of compounds have the potential of specific therapeutics against TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at www.fasgen.com.

Source: FASgen, Inc.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES